Altrenogest, CAS 850-52-2, is a synthetic trienic 19-norprogestin with the chemical name 17α-allyl-17β-hydroxyestra-4,9,11-trien-3-one, molecular formula C₂₁H₂₆O₂, and molecular weight 310.43 g/mol. The product grade described here is Altrenogest Oral Solution Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions. It is supplied as a white to almost white crystalline powder for downstream formulation into multiple finished dose forms. The oral solution presentation is commonly standardized to 2.2 mg/mL (0.22% w/v) in an oil-based vehicle; the active pharmaceutical ingredient itself is controlled against pharmacopoeial and manufacturer release criteria for assay, related substances, residual solvents, water content, and particle size distribution where content uniformity or dissolution is particle-size dependent. In mares, altrenogest is used for estrus suppression and synchronization at a typical daily dose of 0.044 mg/kg body weight by oral administration; in gilts and sows, a common synchronization protocol uses 15 mg/day for 14 days. Published data for some species-specific configurations is limited, and dose selection must follow the registered product or veterinary prescription in the jurisdiction of use.

Why does altrenogest remain a first-line oral progestin when progesterone itself is poorly absorbed by the oral route?

The difference arises from structural features rather than formulation alone. Progesterone is extensively metabolized in the gastrointestinal mucosa and liver, and its oral bioavailability in horses is low. Altrenogest incorporates a 17α-allyl substituent and a conjugated A-ring triene system, which reduces first-pass inactivation and permits clinically effective oral delivery without injection. The 17α-allyl group blocks metabolic oxidation at the 17β-hydroxyl position, while the 4,9,11-triene system changes the stereoelectronic character of the A-ring and reduces conversion to inactive metabolites. This is not a general property of all progestins. Medroxyprogesterone acetate carries a 17α-acetoxy group and a 6α-methyl substituent; norgestomet carries a 17α-acetoxy-11β-methyl-19-nor structure; altrenogest differs from both in its allyl substitution and triene unsaturation. In practice, altrenogest oral solution is administered on a body-weight basis, and the oil-based vehicle is selected to maintain solution stability and dose uniformity. Because the API must be dissolved rather than suspended in the final solution, peroxide value, acid value, and oxidative stability of the vehicle are as critical as the API assay. Where a refined vegetable oil vehicle is used, release tests for the vehicle typically include peroxide value not exceeding 5 mEq O₂/kg and acid value not exceeding 0.5 mg KOH/g, determined by Ph. Eur. 2.5.5 and Ph. Eur. 2.5.1, respectively. For solid dosage forms, dissolution rate becomes a limiting parameter because altrenogest is practically insoluble in water. Formulators often use micronized API with particle size controlled by laser diffraction, for example D₉₀ ≤ 10 µm, to support content uniformity and dissolution in tablets and capsules. This value is dossier-specific and should not be treated as a universal specification.

Milling and blending operations for altrenogest-containing tablets and premixes require containment controls because the compound is a hormonally active steroid. Occupational exposure limits are not harmonized globally; manufacturing suites typically operate with engineering controls such as downflow booths, isolators, or high-efficiency particulate air filtered exhaust. For tablets and capsules, direct compression is generally limited by the low dose and poor flow of micronized altrenogest; wet granulation or dry granulation with lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate is more common. The API is added as a screened powder to the granulation mass or dissolved in a granulating solvent where solubility in ethanol or dichloromethane permits. Batch-to-batch variance in blend uniformity is controlled by stratified sampling according to ASTM E2810-19 or equivalent technical guidance, with acceptance criteria typically set at relative standard deviation ≤ 5.0% and individual values from 90.0% to 110.0% of label claim. For low-dose premixes, geometric dilution steps are used; a 0.5% w/w pre-blend is prepared before final dilution to 0.01% w/w or lower. Bulk density and tapped density of the API and excipients should be measured using USP <616> or Ph. Eur. 2.9.34 to avoid segregation during transfer. Drying temperature for wet granules is selected from forced degradation data; routine drying is often conducted with product temperature not exceeding 50°C because altrenogest is thermally stable under short-term exposure but can degrade under aggressive drying conditions. Published stability data for this specific configuration is limited.

Physicochemical release criteria, residual solvent limits, and micronization controls

Release of altrenogest veterinary-grade API is based on compendial and ICH-linked specifications. The following table lists representative acceptance criteria applied at release and on stability; exact limits may vary by manufacturer and pharmacopoeial monograph edition. Where the API is intended for sterile injection, bacterial endotoxins are tested according to Ph. Eur. 2.6.14 or USP <85>, and the API is sterile-filtered after dissolution. Particle size is not always a compendial requirement, but for poorly water-soluble steroid APIs it becomes a specification in individual marketing authorizations when dissolution or content uniformity is sensitive to particle size.

When altrenogest is crystallized from dichloromethane/heptane, residual dichloromethane is commonly controlled to ≤ 600 ppm, methanol to ≤ 3000 ppm, and heptane to ≤ 5000 ppm, aligning with ICH Q3C options. If the API is micronized by air-jet milling, particle size distribution is controlled by laser diffraction and specific surface area by nitrogen adsorption. Milling can increase amorphous surface content and electrostatic charge, which influences flow and blend uniformity; this is a processing conflict observed in production-scale lots where a micronized grade with D₉₀ > 15 µm can show demixing in a 500 L ribbon blender at fill levels from 40% to 65%. Sampling from top, middle, and bottom locations according to ASTM E2810-19 may show relative standard deviation greater than 8.0% before optimization of charge order and mixing time.

Sterile filtration of altrenogest-loaded solutions for injection presents a different set of constraints from oral solution manufacture. Altrenogest is lipophilic and practically insoluble in water, so injectable presentations usually require a co-solvent system such as benzyl alcohol, ethanol, propylene glycol, or a mixture with sesame oil or ethyl oleate. The selected vehicle must be filtered through a 0.22 µm membrane, but the API itself must be in solution at the point of filtration; submicron particles or crystals retained by the membrane can reduce delivered dose and clog the filter. Filter compatibility testing is performed according to ASTM F838-20 for bacterial retention and with product-specific extractable and leachable protocols aligned to USP <665> and <1665>. Terminal sterilization of oil-based injections may use dry heat or moist heat where the vehicle allows, but altrenogest is not universally stable under all terminal sterilization cycles, so aseptic processing is often required. For capsules, the API is blended with lactose or mannitol and filled into hard gelatin or hypromellose capsules; content uniformity is tested according to USP <905> or Ph. Eur. 2.9.40. A dissolution test may use 0.1 N hydrochloric acid with 0.5% sodium lauryl sulfate as the medium, the apparatus being USP <711> Apparatus 2 operated at 50 rpm and 37°C ± 0.5°C. Published data for this specific configuration is limited and the selection depends on the finished product dossier.

When altrenogest is selected over norgestomet, medroxyprogesterone acetate, or megestrol acetate in veterinary reproductive protocols

Selection is not driven by a single potency value but by species-specific regulatory status, route-specific efficacy, withdrawal period constraints, and formulation availability. Norgestomet is used in cattle as an implant plus injectable estradiol valerate for estrus synchronization; altrenogest is not typically registered for cattle in all jurisdictions. Medroxyprogesterone acetate and megestrol acetate are used in small-animal and human medicine, but their veterinary approval status and safety data in food-producing species differ. Altrenogest is notable for oral activity in mares and gilts/sows, where daily oral dosing suppresses estrus and, in swine, permits synchronization of follicular development after withdrawal. The following comparison summarizes formulation-relevant structural differences.

The difference between altrenogest and progesterone is not simply the 17α-allyl group: altrenogest has no 19-methyl group, and the triene structure differentiates it from 19-nortestosterone-derived progestins. In regulatory terms, altrenogest is controlled as a reproductive toxicant under some occupational safety frameworks; engineering controls are mandatory for powder handling. The API is not intended for use in pregnant women or women of childbearing potential without strict containment and personal protective equipment including nitrile gloves tested to EN ISO 374-1:2016 and protective coveralls.

Because altrenogest is hydrophobic and binds strongly to glass and some polymer surfaces, low-concentration analytical standard solutions should be prepared in silanized glass or polypropylene containers. Aqueous solubility is extremely low; dissolution testing without surfactant can produce incomplete release and high variability. In premix and granule applications, the API is typically incorporated into a carrier such as lactose monohydrate or corncob granules, and homogeneity is demonstrated across the intended use level. In 500 L ribbon blender production, segregation risk increases when the active premix is discharged directly into a bin without a de-agglomerating step; a conical screen mill operated at 1000–1500 rpm may be inserted to break agglomerates and reduce blend uniformity failure. This is an operational boundary for poorly flowable micronized steroid powders, not a limitation of the molecule itself.